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CLINICAL RELEVANCE OF PAIN AND FUNCTION 
OUTCOMES IN GLUCOSAMINE SULFATE LONG-TERM 
TRIALS 
G Giacovelli 1 , O Bruyere 2, B Barbetta 1 , K Pavelka 3, JY 
Reginster 2, LC Rovati 1 
1 Clinical Pharmacology Department, Rottapharm, Monza, Mi, 
Italy; 2Bone and Cartilage Research Unit, University of Liege, 
Liege, Belgium; 3Institute of Rheumatology, Prague, Czech 
Republic 
Aim of Study: The 2005 release of the Cochrane Review on glu- 
cosamine use in osteoarthritis outlined a moderate to large ef- 
fect size on osteoarthritis symptoms in trials using the original 
crystalline glucosamine sulfate prescription preparation. Never- 
theless, a small effect size was pointed out on WOMAC pain and 
function scores. Since the WOMAC index was used only in the 
two long-term 3-year trials with this formulation, we wanted to in- 
vestigate whether the mild severity characteristics of the patients 
enrolled in such particular trials affected this effect size, and if 
the difference observed with placebo was in any case clinically 
relevant, besides being statistically significant. 
Methods: Patients completing the 3-year treatment course in the 
randomised, double-blind, placebo-controlled trials of Reginster 
2001 and Pavelka 2002, were pooled in a single database. The 
Minimal Clinically Important Improvement (MCII) and Patient Ac- 
ceptable Symptom State (PASS) for WOMAC pain and function 
scores, were calculated according to Tubach 2005. The propor- 
tion of patients achieving such thresholds were compared be- 
tween groups by the chi-square test. 
Results: Out of the 259 completers (126 with placebo and 133 
with glucosamine sulfate), over 50% were in PASS at the end of 
the studies regardless of treatment. However, they were 68.4% 
for WOMAC pain with glucosamine sulfate vs. 55.6% with placebo 
(p=0.033), and 63.9% vs. 50.0% on WOMAC function (p=0.024). 
Patients reporting MCII on WOMAC pain were 39.8% vs. 27.8%, 
respectively (p=0.040). 
Conclusions: The mild severity characteristics of the patients 
enrolled in the two long-term trials with glucosamine sulfate al- 
lowed the vast majority of them to be in an acceptable symptom 
state, thus preventing the possibility of observing the moderate 
to large effect size for improvement hat was reported in shorter 
studies. Nevertheless, there was a clinically relevant and signifi- 
cant difference of 10-15% in favor of glucosamine sulfate in the 
proportion of patients reaching MCII and PASS on pain and func- 
tion. 
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EVALUATION OF THE CLINICAL RELEVANCE OF THE 
SYMPTOMATIC EFFICACY OF LUMIRACOXIB IN 
OSTEOARTHRIT IS  UTILISING THE PATIENT 
ACCEPTABLE SYMPTOM STATE (PASS) CONCEPT 
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1Rhumatologie B, Hopital Cochin, Paris, France; 2Novartis 
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Aim: The PASS is an absolute threshold value proposed for 
symptomatic variables in osteoarthritis (OA) to determine the 
point beyond which patients consider themselves well. The PASS 
differs from the baseline-dependent minimal clinically important 
difference. If the patient meets the PASS threshold, they achieve 
an acceptable symptom state regardless of their change from 
baseline in visual analogue scale (VAS) score. This makes the 
PASS a clinically relevant treatment target. In knee OA, PASS 
thresholds (on a 0-100 VAS scale) have been recently proposed 
as 32.3 mm for pain, 32.0 mm for patient's global assessment of 
disease activity and 31.0 mm for the WOMAC TM function subscale 
score. In previous analyses, lumiracoxib 100 mg once daily (od) 
was found to be significantly superior to placebo and non-inferior 
to celecoxib 200 mg od after 13 weeks in knee OA with respect to 
standard OA outcome variables. To assess the clinical relevance 
of these results from the perspective of the patient, the same data 
pooled from two large studies of knee OA were analyzed with re- 
spect to the PASS criteria for knee OA. 
Methods: A total of 3235 patients were included in two multicen- 
ter, randomized, double-blind studies of identical design. Patients 
with an OA pain intensity in the target knee _>40 mm on a 100 
mm VAS were included; no flare was required. After a 3-7-day 
washout of previous NSAID/analgesic therapy, patients were ran- 
domized to receive lumiracoxib 100 mg od (n=811), lumiracoxib 
100 mg od with a loading dose of lumiracoxib 200 mg od for the 
first two weeks (n=805), celecoxib 200 mg od (n=813) or placebo 
(n=806) for 13 weeks. The average effect of the two lumiracoxib 
100 mg od regimens at 13 weeks was contrasted with the ef- 
fects of celecoxib and placebo. Treatments were compared with 
respect to the PASS criteria (for OA pain, patient's global assess- 
ment of disease activity, and the WOMAC TM function [difficulty in 
performing daily activities] sub-scale score). 
Results: Significant proportions of patients on lumiracoxib 
achieved a PASS (all three definitions) and lumiracoxib was sig- 
nificantly superior to placebo (all p<0.05). 
Conclusion: PASS is an important concept in determining the 
clinical relevance of OA treatments. Percentages of patients on 
lumiracoxib 100 mg od who achieved a PASS were similar to 
those on celecoxib 200 mg od and significantly superior to those 
on placebo. This post-hoc analysis using PASS criteria suggests 
that the efficacy of lumiracoxib 100 mg od is of clinical relevance 
from the patient's perspective. 
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A TWO-YEAR FOLLOW-UP OF A RANDOMIZED TRIAL TO 
COMPARE THE EFFICACY OF LATERAL WEDGED 
INSOLES WITH SUBTALAR STRAPPING AND IN-SHOE 
LATERAL WEDGED INSOLES IN PATIENTS WITH VARUS 
DEFORMITY OSTEOARTHRIT IS  OF THE KNEE 
Y Toda, N Tsukimura 
Orthopedic Surgery, Toda Orthopedic Rheumatology Clinic, 
Suita, Osaka, Japan 
Aim of Study: In our previous study, we demonstrated that in- 
soles with subtalar strapping (the strapped insole) maintained 
the valgus correction of the femorotibial angle (FTA) in patients 
with osteoarthritis varus deformity of the knee (knee OA) for six 
months. However, the six-month observation period was too short 
to evaluate the effect of the strapped insole on the progression of 
varus deformity of knee OA. Therefore, we continued to assess 
Abstract P130 - Table 1. Percentage of patients achieving the PASS threshold criteria 
PASS threshold criteria Lumiracoxib 100 mg od (n=1616) Celecoxib 200 mg od (n=813) 
OA pain intensity (100 mm VAS) 832.3 44.3* 42.2* 
Patient global assessment of disease activity (100 mm VAS) 832.0 43.3* 39.5* 
WOMACTM function sub-scale score (100 mm VAS) 831.0 41.5* 38.6* 
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Abstract P131 - Table 1. Comparison of the FTA and Lequesne Index at baseline, month 6 and year 2. 
Strapped insole group (n=21) 
Inserted insole group (n=21) 
FTA (°) Lequesne Index 
Baseline 6-month 2-year Baseline 6-month 2-year 
180.3 ±4.1 180.1 ±3.6 179.7±3.2 10.1 ±4.6 6.5±6.2 7.3±5.6 
180.8±4.6 180.8±4.2 182.4±4.7 9.7±4.2 8.6±5.5 9.6±4.8 
the effect of the strapped insole on the FTA in patients with knee 
OA for two years. 
Methods: The efficacy of the strapped insole and a traditional 
shoe insert wedged insole (the inserted insole), as a positive con- 
trol, were compared at the baseline and after 2 years of treatment. 
Randomization was performed according to birth date. The 61 
female outpatients with knee OA who completed the six-month 
study continued to receive treat with their respective insoles. The 
FTA was assessed by standing radiographs obtained while bare 
foot and the Lequesne index of knee OA at two years was com- 
pared with those at baseline in each insole group. 
Results: There were 61 patients in the original study, but 19 
(31.1 %) withdrew. The 42 patients who completed the two-year 
study were evaluated. At the baseline assessment of the 42 pa- 
tients, there was no significant differences in the FTA (P=0.73) 
or the Lequesne index (P=0.78), between the two groups. At 
the two-year assessment, the FTA was reduced by an average 
of 0.6204-2.6 ° in the strapped insole group (n=21), compared to 
the baseline assessment. However, the FTA was increased by 
1.704-3.5 ° compared with the period before the use of an insole 
in the inserted insole group (n=21). These changes represented 
a significant difference between the strapped and inserted in- 
sole groups (P=0.021). Compared with the initial assessment, 
the remission score, indicated by the Lequesne index at the two- 
year assessment, showed significantly greater improvement in 
the strapped insole group (-2.74-3.8) than in the inserted insole 
group (-0.144-4.1), (P=0.042). 
Conclusion: In this study, only those participants using the sub- 
talar strapped insole demonstrated no change in the femorotibial 
angle in comparison with the baseline assessments. If the insole 
with a subtalar strap maintains femorotibial angle for more than 
two years, it may restrict he progression of degenerative articular 
cartilage lesions of knee OA. We plan to continue monitoring our 
subjects for an additional 5 to 10 years in order to determine the 
long-term effect of the strapped insole. 
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DYNAMIC JOINT LOADING ALTERATIONS ARE 
ASSOCIATED WITH RADIOGRAPHIC SEVERITY BUT 
NOT PAIN IN SUBJECTS WITH UNILATERAL HIP 
OSTEOARTHRITIS (OA) 
N Shakoor 1 , L Thorp 2, JA Block 1 
1 Section of Rheumatology, Rush Medical College, Chicago, IL; 
2Department of Anatomy, Rush Medical College, Chicago, IL 
Introduction: Dynamic joint loading has been shown to be im- 
portant in the pathophysiology of lower extremity osteoarthritis. 
Previous small studies have suggested that subjects with end- 
stage hip osteoarthritis (OA) have decreased peak external mo- 
ments at the affected hip compared to normal subjects. However, 
whether these alterations are initiated early in the evolution of 
symptomatic hip OA or associated with the radiographic severity 
of hip OA is still not clear. The purpose of this investigation was to 
examine dynamic joint loading at the hips of subjects with varying 
degrees of radiographic and symptomatic unilateral hip OA. 
Methods: 34 subjects with unilateral symptomatic hip OA and 
16 age-matched normal subjects were evaluated. Subjects had 
mild to severe radiographic hip OA. Seven subjects had Kell- 
gren Lawrence (KL) grade 1 hip OA, 8 had KL grade 2, 11 had 
KL grade 3, and 7 had KL grade 4 hip OA. Gait analyses were 
performed using an optoelectronic amera system and multi- 
component force plate. Inverse dynamics were used to calculate 
peak moments at the joints and determine range of motion at the 
joints. Pain was assessed using the Western Ontario MacMasters 
Universities Osteoarthritis Index (WOMACTM). Spearman correla- 
tions were used to correlate peak moments with KL grade and 
pain at the affected hip. Independent samples t-test were used to 
compare normal subjects with the hip OA subjects. 
Results: Significant correlations were found between dynamic 
joint loads and KL grade at the affected hip. KL grade was in- 
versely correlated with the peak hip flexion moment (rho=-0.554, 
p=0.001), hip internal rotation moment (rho=-0.580, p=0.001), hip 
extension moment (rho=-0.386, p=0.05) and hip range of motion 
(rho=-0.698, p<0.001). There was no correlation between peak 
hip moments and pain at the affected hip. There was also no sig- 
nificant correlation between KL grade at the affected hip and peak 
moments at the contralateral hip. When comparing subjects with 
mild to moderate unilateral hip OA (KL grade 1 through 3) with 
normal subjects, the hip OA subjects had significantly lower peak 
hip flexion (p=0.016), adduction (p<0.001), and internal rotation 
moments (p=0.05). Interestingly, these subjects also had signifi- 
cantly lower peak knee extension (p=0.032) and knee adduction 
moment (p=0.013) at the ipsilateral limb compared to normal sub- 
jects. 
Conclusion: Subjects with unilateral hip OA have lower peak dy- 
namic loads at the affected hip and ipsilateral knee when com- 
pared to normal subjects. This decrease in joint loads occurs 
early in the course of unilateral hip OA and is correlated with ra- 
diographic severity of hip OA. Furthermore, this decrease in joint 
loads appears to be independent of pain at the affected hip. Fu- 
ture studies should evaluate what factors may contribute to these 
alterations in loading and how these alterations may influence the 
progression of lower extremity OA in these subjects. 
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ORAL CALCITONIN PROTECTS AGAINST 
EXPERIMENTIALLY INDUCED OSTEOARTHRITIS 
BC Sondergaard, S Ostergaard, P Qvist, LB Tank6, C 
Christiansen, MA Karsdal 
Pharmacology and Biomarkers, Nordic Bioscience & Center for 
Clinical and Basic Research, Herlev/Ballerup, Denmark 
Purpose: To investigate whether oral calcitonin treatment influ- 
ences the rise in cartilage degradation accompanying estrogen 
deficiency, and whether calcitonin has any direct effects on chon- 
drocytes in this context. 
Methods: Fifty rats aged seven months were randomly allocated 
into five intervention groups. Rats undergoing bilateral ovariec- 
tomy (OVX) were used to mimic the hormonal status characteris- 
tic for the menopause. The five intervention groups were as fol- 
lows: 1) Sham, 2) OVX, 3) OVX+estrogen, 4) OVX+2mg/kg cal- 
citonin plus 50mg/kg 5-CNAC, and 5) OVX + 50mg/kg 5-CNAC. 
Each treatment was administered for six weeks after OVX. Fast- 
ing blood samples for biomarker analysis were taken at base- 
line, day 3, and weeks 1, 2, 4, and 6. Cartilage degradation was 
quantified by measuring the changes in the concentration of C- 
telopeptides of collagen type II (CTX-II ELISA), and the changes 
in the severity scores of articular cartilage erosions visualized in 
